This report explores the impact of calls to rapidly and openly share Covid-19 research findings to inform public health response, as recommended in our 2020 Joint Statement.
Showing 1 to 20 results of 456
Sorted by most recent
Understanding the antibiotic manufacturing ecosystem
Combining climate and health data: challenges and opportunities for longitudinal population studies
This report looks at whether longitudinal population studies could be a useful way to research the impact of climate change on health.
Covid-19 vaccines: the factors that enabled unprecedented timelines for clinical development and regulatory authorisation
This report identifies the factors that enabled the rapid clinical development and emergency use authorisation of Covid-19 vaccines.
The Wellcome CPD Challenge: Pilot Delivery Report
The Wellcome CPD Challenge: Evaluation Final Report
Landscape mapping of software tools for climate-sensitive infectious disease modelling
A report that identifies what software tools exist for modelling the relationship between climate and infectious diseases.
Creating a publicly-led research agenda for Long Covid
A research agenda outlining priorities to inform the direction of future research on Long Covid.
Wellcome Trust Annual Report and Financial Statements 2021
Wellcome Trust Finance plc Annual Report and Financial Statements 2021
Wellcome Trust Limited Annual Report and Financial Statements
Wellcome's Annual Report 2021 describes our activities during the past year, and reviews our finances and investments.
Wellcome Global Monitor 2020 Covid-19
How the Covid-19 crisis has affected people around the world and influenced their trust in science, healthcare systems and governments.
This paper outlines three areas – global coordination and leadership; financing and how to address key gaps in pandemic infrastructure – that will have the biggest impact on future global preparedness.
Across the world, there are unacceptable disparities in access to Covid-19 vaccines, leaving many vulnerable people unprotected. This paper considers this challenge and sets out the action needed by G20 countries and vaccine manufacturers to rapidly increase global vaccination rates, with the aim of reaching 70% of the population in every country by June 2022.
This report explores the barriers to vaccine development for important infectious disease threats. It looks at vaccines that lack clear commercial markets, but target diseases that cause major loss of life, disability and illness, or risk being the source of future epidemics.